Neobona Non-Invasive Prenatal Test for Diagnosis of Pregnancy Baby

Preparing for the child

What I would have liked during Maria’s pregnancy had been able to opt for a Non-Invasive Prenatal Test like this (you know it was a very complicated high-risk pregnancy, as you can see in this post ) … that of dislikes that I would have saved, although reading in forums and others, there may be some margin of error, so there are people who after the Triple Screening result, in addition, are tested for amniocentesis.

Chromosomal abnormalities, such as trisomy 21 (Down syndrome), are present in 1-2% of fetuses. There is a wide range of tests available to assess the correct development of the future baby before birth. SYNLAB is the pioneer laboratory in molecular prenatal diagnosis thanks to the incorporation of new scientific advances to offer a state-of-the-art non-invasive prenatal test, Neobona, backed by the experience and reliability of one of the leading European laboratories.

NeoBona provides parents with confidence, as it allows the detection of chromosomal abnormalities in the fetus in the first months of pregnancy. It is a non-invasive test, without any risk to the future baby, which allows us a fairly reliable prenatal diagnosis.

What is this Neobona Non-Invasive Prenatal Test?

The test only requires a sample of maternal blood and the analysis is performed using the innovative WGS paired-end sequencing technique that replaces the conventional method with simple readings. This technology allows a new, more effective study of free DNA, improving the differentiation between free fetal and maternal DNA and accuracy in the detection of chromosomal abnormalities. This technology is offered exclusively by SYNLAB.

The fetal free DNA fraction is a crucial parameter that influences the accuracy of the analysis. Unlike other tests, neoBona specifically analyzes the amount of fetal free DNA through the analysis of the size of free DNA fragments, thus allowing the highest accuracy to be achieved.

This technology allows obtaining results in the vast majority of cases (sample repetition rate of 1.5%).

Global sensitivity is greater than 99% for Down, Edwards, and Patau syndromes.

From when can you do it?

The test is indicated from the 10th week of gestation (10 weeks + 0 days), for single and twin pregnancies (two fetuses), including IVF with a donation of gametes.

NeoBona is a genetic screening test and as such should be prescribed by a doctor, so it is best to ask and inform yourself with your doctor or your trusted doctor.

Types of tests

There are different tests and according to the one we choose, they will detect a wide range of screening possibilities for one disease or another in the baby. Obviously, the more advanced, the more it costs us economically speaking and the more complete it is.

Leave a Reply